Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma

U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib primarily based on follow-up data from the pivotal Phase II study CHRONOS-1 ...

100 new young leaders join the journey towards Zero Hunger

The biennial Bayer Youth Ag Summit brings together 100 young food security activists to develop concrete projects to help feed a hungry planet / The 2019 Summit will take place from 4-6 November in Brasilia, Brazil / Bayer received over 2,800 applications from more than 140 countries ...

Bayer announces 5-year partnership with the World Federation of Hemophilia Humanitarian Aid Program

The donation of Factor VIII treatments will support as many as 5,000 people living with hemophilia A in countries with insufficient access to care ...

Bayer launches Baycox® Iron Injection combination in Europe

The first and patented toltrazuril plus gleptoferron injectable combination available in Europe helps protect suckling piglets ...

Collaboration to focus on driving novel technologies and applications for animal health and nutrition

Industry experts and scientists will discuss strategies for future weed, disease and pest control in agriculture

New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastases

In children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) not reached / ...

Bayer statement on jury’s decision in California State Glyphosate Trial

Beiersdorf to acquire iconic Coppertone™ brand from Bayer

Significant expansion of portfolio will advance Beiersdorf’s leading position as sun care expert ...

Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigm

Data from Bayer’s growing oncology portfolio include new analyses on the company’s precision oncology treatment larotrectinib ...